NCT07199777Not yet recruitingPhase 2
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 22 Sept 2025
- Start date
- Nov 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- SciNeuro
- Diseases
- Diabetic eye disease
- NCT number
- NCT07199777
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From Nov 2025 to the primary completion date, Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Main Inclusion Criteria:
- Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control
- Center-involved DME with CST \>=320 µm (Study eye)
- BCVA between 82 and 25 letters, inclusive (Study eye)
- BCVA score ≥ 25 letters (Non-study eye)
- Main Exclusion Criteria:
- 1\. Use of the last intravitreal anti-VEGF injection in the study eye within 90 days prior to Screening
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.